Latest News and Press Releases

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and host one-on-one investor meetings during the virtual...

CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target...

CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the “Company”) today announced the appointment of Jay M. Feingold, M.D., Ph.D., as Chief Medical Officer. “Jay’s...

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the “Company”) today announced the appointments of Freda Lewis-Hall, M.D., Thomas Civik, Darren Cline, and Mark Chin...

CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the “Company”) today announced the recent appointment of Pamela Yanchik Connealy, M.B.A., as its Chief Financial...

– Steve Monks, Ph.D., appointed as Chief Technical Officer, brings 20+ years in drug development and CMC, Quality, and Regulatory operations – – Ritu Shah, PMP, appointed as Chief Operating Officer,...

LEXINGTON, Mass. and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Alloy Therapeutics (“Alloy”) and Pyxis Oncology ("Pyxis") today announced the formation of a joint venture named Kyma...

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the "Company") today announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional...

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the "Company") today announced that it will host a key opinion leader (KOL) webinar on antibody-drug conjugates on...

-- New round enables Pyxis to advance differentiated antibody-drug conjugate (ADC) and immuno-oncology (I/O) programs to next value inflection point -- -- In addition to recently announced...